Table 2.
Non-cardiac baseline prognostic survival factors and associated effects assessed by multivariate analysis
| Domaina | Description | Survival difference (years) | Mitigating factor(s) |
|---|---|---|---|
| Genotype | |||
| Mariani, 2015 [36] | Val30Met vs. Non-Val30Met | 1 (8 vs. 7) | Among No LTx |
| Mariani, 2015 [36] | Val30Met vs. Non-Val30Met | 4 (17 vs. 13) | Among LTx |
| Sex/gender | |||
| Munar-Ques, 2005 [37] | Female vs. male | − 1 (9 vs. 10) | None reported |
| Okamoto, 2009 [40] | Female vs. male | ≥ 4 (≥ 25 vs. 21) | Among LTx |
| Okamoto, 2009 [40] | Female vs. male | ≥ 4 (≥ 25 vs. 21) | Among LTx with early onset |
| Okamoto, 2009 [40] | Female vs. male | ≥ 9 (≥ 20 vs. 11) | Among LTx with late onset |
| Yamamoto, 1998 [48] | Female vs. male | 1 (11 vs. 10) | Among no LTx |
| Pre-LTx disease duration | |||
| Bittencourt, 2002 [24] | < 7 years vs. ≥ 7 years | ≥ 6 (≥ 7 vs. 1) | None reported |
| Okamoto, 2009 [40] | < 7 years vs. ≥ 7 years | ≥ 4 (≥ 25 vs. 21) | None reported |
| Suhr, 2002 [43] | < 7 years vs. ≥ 7 years | 3 (14 vs. 11) | Lower baseline mBMI in < 7 years |
| Yamamoto, 2007 [49] | < 7 years vs. ≥ 7 years | ≥ 17 (≥ 20 vs. 3) | None reported |
| Biometrics/symptoms | |||
| Suhr, 2002 [43] | mBMI > 600 vs. < 600 (at LTx) | 3 (14 vs. 11) | Pre-LTx disease duration was < 7 vs. ≥ 7 years |
| Yamamoto, 2007 [49] | mBMI > 600 vs. < 600 (at LTx) | ≥ 17 (≥ 20 vs. 3) | Pre-LTx disease duration was < 7 vs. ≥ 7 years |
| Bittencourt, 2002 [24] | Serum albumin (at LTx) | ≥ 6 (≥ 7 vs. 1) | Among LTx |
| Adams, 2000 [19] | Urinary incontinence (at LTx) | ≥ 4 (≥ 5 vs. 1) | Among LTx |
mBMI Modified body mass index
aPresented as first author of study, year of publication [reference number]